Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen
This study has demonstrated that more than two-thirds of the women on vaginal tamoxifen improved in their most troublesome VVA symptom. This is likely due to a tamoxifen-induced estrogen agonistic effects in vagina in a low-estrogen environment. While findings are promising, further studies on improved vaginal administration and endometrial safety concerns are needed.
Authors
- Helena Kopp Kallner (ORCID: https://orcid.org/0000-0001-7184-9165)
- Inger Sundström Poromaa (ORCID: https://orcid.org/0000-0002-2491-2042)
- Sara Nyback
- Theodora Kunovac Kallak (ORCID: https://orcid.org/0000-0002-2112-8674)
- Angelica Lindén Hirschberg
- Henrik Lindman
- Anna Wikman
Institutions
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- Danderyds sjukhus (SE)
- Karolinska Institutet (SE)
- Glanrhyd Hospital (GB)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1016/j.ejca.2026.116261
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Falk Foundation
- Swedish Cancer Foundation
- Percy Falk Foundation
- Magnus Bergvalls Stiftelse